Kelly Foster

C3J Therapeutics (United States) — United States

Medicine · Health Sciences

13h-index919citations58works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sympathectomy and Hyperhidrosis Treatments(7), Thyroid Disorders and Treatments(6), Ophthalmology and Eye Disorders(6), Peptidase Inhibition and Analysis(6), Neonatal Respiratory Health Research(5)

Publications58 total

Preclinical pharmacology, pharmacokinetics, and pharmacodynamics of veligrotug, a full antagonist antibody to the IGF-1 receptor in development for thyroid eye disease
mAbs·2025· 1 citedOpen Access
Abstract 4258: FL-501 is a potential best in class GDF-15 inhibitor with extended half-life and potent anti-cachexia activity in preclinical models
Cancer Research·2025
6461 VRDN-003, a Full Antagonist Antibody to the IGF-1 Receptor for Thyroid Eye Disease (TED): Safety and Pharmacokinetic Results of Subcutaneous Administration in Healthy Volunteers
Journal of the Endocrine Society·2024· 2 citedOpen Access
6461 VRDN-003, A Full Antagonist Antibody To The IGF-1 Receptor For Thyroid Eye Disease (TED): Safety And Pharmacokinetic Results Of Subcutaneous Administration In Healthy Volunteers
Journal of the Endocrine Society·2024· 1 citedOpen Access
VRDN-003, a full antagonist antibody to IGF-1R for thyroid eye disease (TED): phase 1 results show potential for subcutaneous administration
Endocrine Abstracts·2024· 1 cited
A Phase 1 Single-Ascending-Dose Trial in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravenous PNT001, a Novel Mid-domain Tau Antibody Targeting cis-pT231 Tau
The Journal of Prevention of Alzheimer s Disease·2024· 13 citedOpen Access
Social Network Analysis as a Driver of Continuous Improvement
Journal of School Administration Research and Development·2023Open Access
FRI546 VRDN-001, A Full Antagonist Antibody To IGF-1 Receptor In Development For Thyroid Eye Disease (TED): Pharmacodynamic Responses In Healthy Volunteers And Patients With Active TED
Journal of the Endocrine Society·2023· 1 citedOpen Access
Identifying Gene-Treatment Interactions and Targetable Radiation Vulnerabilities in Glioblastoma through Coupling of In Vivo CRISPR Perturbation and Single Cell Transcriptomics
International Journal of Radiation Oncology*Biology*Physics·2023· 1 citedOpen Access
Preclinical pharmacokinetics and clinical exposure prediction for VRDN-003, a next-generation half-life extended antibody to the IGF-1 receptor for thyroid eye disease
Endocrine Abstracts·2023· 1 cited
Phase 1 Safety and Pharmacodynamic Results of VRDN-001, a Full Antagonist Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R) in Development for Thyroid Eye Disease (TED) (P3-9.007)
Neurology·2023· 2 cited
Preclinical characterization and IND‐enabling safety studies for PNT001, an antibody that recognizes <i>cis</i>‐pT231 tau
Alzheimer s & Dementia·2023· 14 citedOpen Access
Supplementary Figure Legends from LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
2023Open Access
Table S1 from LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
2023Open Access
Supplementary Fig. S3 from ABT-263 and rapamycin act cooperatively to kill lymphoma cells &lt;i&gt;in vitro&lt;/i&gt; and &lt;i&gt;in vivo&lt;/i&gt;
2023Open Access
Table S1 from LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
2023Open Access
Supplementary Fig. S1 from ABT-263 and rapamycin act cooperatively to kill lymphoma cells &lt;i&gt;in vitro&lt;/i&gt; and &lt;i&gt;in vivo&lt;/i&gt;
2023Open Access
Data from ABT-263 and rapamycin act cooperatively to kill lymphoma cells &lt;i&gt;in vitro&lt;/i&gt; and &lt;i&gt;in vivo&lt;/i&gt;
2023Open Access
Supplementary Fig. S2 from ABT-263 and rapamycin act cooperatively to kill lymphoma cells &lt;i&gt;in vitro&lt;/i&gt; and &lt;i&gt;in vivo&lt;/i&gt;
2023Open Access
Supplementary Figure Legends from LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Brent Dickinson(7), Vahe Bedian(7), Scott Ackler(5), Michael J. Mitten(5), Anatol Oleksijew(5), Marion Refici(5), Sally Schlessinger(5), Baole Wang(5), Sanjay R. Chemburkar(5), Joy Bauch(5), Christin Tse(5), David J. Frost(5), Stephen W. Fesik(5), Saul H. Rosenberg(5), Steven W. Elmore(5), Alex R. Shoemaker(5), Andreas Schibler(4), Hannah Ishmael(4), Ego Ahaiwe Sowinski(4), Etienne Joseph(4)